McKesson Corporation (MCK) Strong Quarter Spurs Analyst Confidence

McKesson Corporation (NYSE:MCK) is one of the best blue-chip stocks to buy now. On November 6, Morgan Stanley raised its price target on McKesson Corporation (NYSE:MCK) to $916 from $857, keeping its Overweight rating. Analysts pointed to the company’s strong organic growth and operational momentum reflected in updated guidance, though they noted investor reaction could be restrained given the high expectations already priced in.

A day earlier, on November 5, McKesson posted second‑quarter results for Fiscal 2026. Revenue climbed 10% to $103.2 billion, helped by rising prescription volumes and broader distribution of oncology and multispecialty products. Earnings per share jumped to $8.92, compared with $1.87 a year ago, as the company moved past charges tied to earlier divestitures and restructuring.

Operating cash flow reached $2.4 billion, with free cash flow at $2.2 billion. In the first half of the fiscal year, McKesson returned $1.6 billion to shareholders through buybacks and dividends, underscoring its focus on capital returns.

Looking ahead, the company lifted its adjusted earnings guidance to $38.35–$38.85 per share for Fiscal 2026. CEO Brian Tyler said record revenue and earnings highlight McKesson’s strength in oncology, multispecialty, and biopharma services, adding that the company is well positioned to deliver long‑term value.

McKesson Corporation (NYSE:MCK) is a diversified healthcare services company that distributes pharmaceuticals and medical-surgical supplies.

While we acknowledge the potential of MCK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 9 Undervalued Asset Management Stocks to Buy and 13 Best AI Stocks to Buy Under $20.

Disclosure: None. This article is originally published at Insider Monkey.